Moderna reports higher international COVID vaccine sales
Statements (49)
- Bullish
Moderna stock surged nearly 150% over the past year following a significant FDA win.
- Bullish
Moderna shares spiked after the company detailed its future beyond COVID-19 at its Science Day event.
- Bullish
Moderna shares are likely to continue rising as investors react positively to the company's detailed future plans beyond COVID-19.
- Bullish
Moderna (MRNA) surged 15% to $68.77 on FDA flu vaccine panel endorsement for mFlusiva.
- Neutral
Moderna is struggling to shake the label of a Covid vaccine winner.
- Neutral
Moderna is struggling to shake the label of a Covid vaccine winner.
- Bullish
Moderna shares jumped 9.1% in the afternoon session
- Bullish
Moderna's year-to-date rally extended to +94%, the best performer in the vaccine cohort
- Bullish
Moderna's year-to-date rally extended to +94%, the best performer in the vaccine cohort
- Bullish
Moderna (MRNA) is likely to continue outperforming Pfizer (PFE) and Novavax (NVAX) in the vaccine sector due to its significantly higher year-to-date stock gain.
- Neutral
Moderna is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020.
- Bullish
Moderna and Merck presented positive long-term data for personalized mRNA-based cancer vaccine
- Bullish
Moderna shares are likely to continue rising as the company and Merck present positive long-term data for their personalized mRNA-based cancer vaccine.
- Bullish
Moderna shares rose 5.1% in the afternoon session
- Neutral
Moderna reports strong five-year cancer vaccine data from KEYNOTE-942 trial
- Neutral
Moderna is receiving up to $50 million to accelerate the development of an Ebola vaccine
- Bullish
Moderna shares jumped 10.2% in the afternoon session
- Bullish
Moderna announced positive Phase 1 data for its hantavirus vaccine
- Bullish
Moderna shares are likely to continue rising following positive Phase 3 clinical trial results for its seasonal flu vaccine candidate.
- Bullish
Moderna published positive Phase 3 clinical trial results for its seasonal flu vaccine candidate mRNA-1010
- Bullish
Moderna stock rose 8% in premarket on Monday
- Bullish
Moderna is developing a vaccine targeting hantavirus
- Bullish
Moderna Inc. shares surged by more than 15% on Friday after the company revealed it is working with the Vaccine Innovation Center at Korea University.
- Bullish
Moderna Inc. is likely to see significant price appreciation due to its announcement of collaboration with the Vaccine Innovation Center at Korea University.
- Bullish
Moderna Inc. shares surged by more than 15% on Friday
- Bullish
Moderna Inc shares are trading higher on Friday morning
- Bullish
Moderna Inc (MRNA) is likely to see increased trading volume and price appreciation due to positive Phase 3 flu vaccine data.
- Bullish
Moderna shares are likely to rise significantly due to heightened investor fear of Hantavirus outbreaks affecting its research and development operations.
- Bullish
Moderna stock rallied due to fears of Hantavirus
- Neutral
Moderna announced publication of Phase 3 study results evaluating mRNA-1010 in the New England Journal of Medicine.
- Bullish
Novavax is likely to see its stock price rise due to its first-quarter revenue exceeding estimates from vaccine deal strength.
- Bullish
Novavax reported first-quarter revenue that exceeded analyst estimates.
- Bullish
Moderna reported Q1 CY2026 revenue of $389 million, exceeding market expectations.
- Bullish
Moderna reported first-quarter sales of $389 million, exceeding expectations.
- Bullish
Moderna shares are likely to continue rising as the company reported first-quarter sales that exceeded expectations, signaling potential growth outside the US.
- Bullish
Moderna shares rose 5.4% following the reported sales figures.
- Bullish
Moderna Inc. reported revenue topped Wall Street expectations
- Neutral
Moderna reported first-quarter financial results on Friday
- Bullish
Moderna is likely to see its stock price rise due to strong international vaccine sales exceeding analyst forecasts.
- Bullish
Moderna's first-quarter revenue exceeded analyst forecasts, tripling year over year.
- Bullish
Moderna stock price spiked following its earnings report
- Bullish
Moderna is likely to see its stock price rise due to reported growth in Covid vaccine revenue.
- Bullish
Moderna Inc. is likely to see its stock price rise significantly due to its Q1 revenue exceeding expectations.
- Bullish
Moderna Inc. reported Q1 revenue of $389 million for fiscal 2026
- Bullish
Moderna reported higher sales of COVID-19 vaccines outside the United States than expected
- Bullish
Moderna is likely to see increased demand for its stock as it reports higher-than-expected sales outside the US.
- Neutral
Moderna reported higher revenue in the first quarter due to increased sales of Covid-19 vaccines in international markets.
- Bullish
Moderna reported higher than expected quarterly revenue on stronger international COVID vaccine sales
- Bullish
Moderna is likely to see its stock price rise due to stronger international COVID vaccine sales exceeding quarterly estimates.